Diagnostic, Technical and Medical
|
|
- Rosamond Ryan
- 5 years ago
- Views:
Transcription
1 Diagnostic, Technical and Medical Approaches to Reduce CABG Related Stroke Pieter Kappetein, Michael Mack, M.D. Dept Thoracic Surgery, Rotterdam, The Netherlands Baylor Healthcare System Dallas, TX
2 Background Risk of Stroke Neurological deficit > 72 hours In hospital/ 30 days CABG STS Database , n= 774,881 Stroke =1.4% PCI NCDR Database, , n=706,782 Stroke = 0.22 % SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 2
3 CVA (Stroke) to 12 Months CABG (N=897) TAXUS (N=903) (%) 20 P=0.003 * Cumu ulative Ev vent Rate Months Since Allocation Event rate ± 1.5 SE. * Fisher exact test 2.2% 0.6% ITT population SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 3
4 In SYNTAX, with CABG one is trading a stroke for repeat revascularization. Who wouldn t want to risk repeat revascularization with PCI rather than a stroke with CABG Common interventional cardiologist s interpretation of Syntax results
5 CVA to 3 Years CABG (N=897) TAXUS (N=903) P=0.07 Cumula ative Even nt Rate (% %) Before 1 year * 1-2 years * 2-3 years * 2.2% vs 0.6% 0.6% vs 0.7% 0.5% vs 0.6% P=0.003 P=0.82 P= % 2.0% Months Since Allocation Cumulative KM Event Rate ± 1.5 SE; log-rank P value;*binary rates EACTS 2010 Three-year Outcomes of the SYNTAX Trial Kappetein Slide 5 ITT population
6 Patients with Stroke in SYNTAX Randomized Cohort, Intent-to-Treat Enrolled N=1800 CABG TAXUS * n=897 n=903 1 Year Follow-up N=1740 (96.7%) CABG TAXUS * n=849 n=891 Stroke n=19 Stroke n=5 * TAXUS Express SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 6
7 Outcomes Following Stroke (Per Patient) CABG (n=19) PCI (n=5) Death 10.5% (n=2) Non-fatal stroke 89.5% (n=17) Non-fatal stroke 100% (n=5) SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 7
8 Stroke With CABG Causes Preoperative Intraoperative Postoperative SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 8
9 Timing of Stroke CABG PCI Total 30 (2.8%) 18 (1.4%) Pre-procedure 3(03%) (0.3%) 0 Procedural- 30 days 9 (1%) 2 (0.2%) 30 days- 1Y Year 7(08%) (0.8%) 3(03%) (0.3%) 1-2 Years 6 (0.6%) 7 (0.7%) 2-3 Years 5 (0.5%) 6 (0.6%) SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 9 Syntax September 3, 9
10 Timing of Stroke CABG PCI Total 30 (2.8%) 18 (1.4%) Pre-procedure 3(03%) (0.3%) 0 Procedural- 30 days 9 (1%) 2 (0.2%) 30 days- 1Y Year 7(08%) (0.8%) 3(03%) (0.3%) 1-2 Years 6 (0.6%) 7 (0.7%) 2-3 Years 5 (0.5%) 6 (0.6%) SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 10 10
11 Stroke With CABG Risk Factors Preoperative Intraoperative Postoperative SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 11
12
13 Early -35% Delayed- 65% Female Prior Stroke Female Prior Stroke Aortic Aortic Atherosclerosis Atherosclerosis Duration of CPB Diabetes Atrial Fibrillation SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 13
14 EACTS 2010 Three-year Outcomes of the SYNTAX Trial Kappetein Slide 14
15 Metabolic Syndrome Stroke Rate 4.7% vs 2.1% EACTS 2010 Three-year Outcomes of the SYNTAX Trial Kappetein Slide 15
16 EACTS 2010 Three-year Outcomes of the SYNTAX Trial Kappetein Slide 16
17 EACTS 2010 Three-year Outcomes of the SYNTAX Trial Kappetein Slide 17
18 Periprocedural Multivariate Predictors of Stroke at 12 Months Predictors by Treatment tarm 12 P CABG (n=897) Odds Ratio ± 95% CI OR 95% CI value Poor or moderate LVEF , 18.4 <0.001 Prior MI 0.1 0, Age , TAXUS (n=903) Hyperlipidemia Female , , Time to treatment , Reduced Increased 0 *TAXUS Express SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 18
19 Stroke With CABG Risk Factors Preoperative Intraoperative Postoperative SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 19
20 Timing of Stroke CABG PCI Total 25 (2.8%) 12 (1.4%) Pre-procedure 3(03%) (0.3%) 0 Procedural- 30 days 9 (1%) 2 (0.2%) 30 days- 1Y Year 7(08%) (0.8%) 3(03%) (0.3%) 1-2 years 6 (0.6%) 7 (0.7%) SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 20 Syntax September 3, 20
21 CVA to 12 Months by SYNTAX Score Tercile CABG TAXUS 12 Mon nth Event Rate, % P=0.10 P=0.21 P= Scores 0-22 Scores Scores 33 KM Event Rate; chi-square test RCT ITT pts; site-reported data SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 21
22 Stroke With CABG Risk Factors Intraoperative Aortic Atherosclerosis Aortic Manipulation Cardiopulmonary Bypass Cerebral Perfusion On pump vs. Off pump SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 22
23 Procedural Characteristics Notable Differences CABG RCT + Registry Procedure-related CABG RCT * (n=897) CABG Reg (n=644) Off-pump surgery, % Graft revascularization, % At least one arterial graft Arterial graft to LAD LIMA + venous Double LIMA/RIMA Complete arterial revascularization Venous graft only Grafts per patient, mean ±SD 2.8 ± ± 0.9 Distal anastomoses, mean ±SD 3.2 ± ± 1.0 * SYNTAX: Stroke TCT 2009 M.J. Mack For descriptive purposes only; no statistical comparisons done San Francisco, CA 22sep2009 Slide 23
24 Procedural Characteristics Potential Risk Factors for Stroke CABG N=897 TAXUS N=903 P value Urgent Procedure, % Emergent Procedure, % Time to procedure, d, mean ± SD 17.4 ± ± 13.0 <0.001 Off-pump surgery % Off Pump On Pump P value Stroke 1/134 (0.7%) 18/763 (2.3%) ns Site-reported data Allocation to procedure For PCI patients, includes time for staged procedure
25 EACTS 2010 Three-year Outcomes of the SYNTAX Trial Kappetein Slide 25
26
27 Risk Factors, and Outcomes Associated With Stroke After Coronary Artery Bypass Grafting.more than half of strokes occurred postoperatively rather than intraoperatively JAMA. 2011;305(4): SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 27
28 EACTS 2010 Three-year Outcomes of the SYNTAX Trial Kappetein Slide 28
29 SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 29
30 Ascending Aortic Atherosclerosis SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 30
31 Ascending Aortic Atherosclerosis SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 31
32 Stroke With CABG Risk Factors Preoperative Intraoperative Postoperative SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 32
33 Timing of Stroke CABG PCI Total 25 (2.8%) 12 (1.4%) Pre-procedure 3(03%) (0.3%) 0 Procedural- 30 days 9 (1%) 2 (0.2%) 30 days- 1Y Year 7(08%) (0.8%) 3(03%) (0.3%) 1-2 years 6 (0.6%) 7 (0.7%) Syntax September 3, 33
34 Medications Potential Risk Factors for Stroke Pre/periprocedural p Medication CABG N=897 TAXUS N=903 P value Aspirin, % <0.001 Heparin (unfractionated), % <0.001 Heparin (low molecular weight), % Bivalirudin, % <0.001 Thienopyridine, % < Aprotinin, % Medication at Discharge Aspirin, % <0.001 Thienopyridine, % <0.001 Coumadin, % < Statin, % Site-reported data
35 Medications at 12 Months Potential Risk Factors for Stroke CABG N=897 TAXUS N=903 P value Aspirin, % <0.001 Statin, % Beta blockers, % ACE inhibitors, % Thienopyridines, % <0.001 Diuretics, % Calcium channel blockers, % Angiotensin II receptor antagonists, % Nitrates <0.001 Oral antidiabetic, non insulinsensitizer, % H2-receptor blockers, % Medications taken by 10% of patients in either group. Site-reported data
36 Adverse Cardiac Events to 12 Months CABG (n=19) 6 patients experienced atrial fibrillation (1 patient had an additional ST elevation MI); in 2 of these patients, the arrhythmia possibly led to the stroke 13 -no adverse cardiac events PCI (n=5) 3 patients had cardiac events (cardiac failure, angina, ST+MI) 2 -no adverse cardiac events SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 36
37 30 day Mortality and stroke higher in the 24% of patients with AF (2.4 % vs 19%) 1.9%) SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 37
38 Antiplatelet Therapy Status at Time of Stroke (Per Patient) Neither 26.3% (n=5) Unknown 10.5% (n=2) CABG (n=19) Aspirin i 52.6% (n=10) PCI (n=5) Dual Antiplatelet Therapy 80.0% (n=4) Clopidogrel Dual Antiplatelet only Therapy 53%(n=1) 5.3% 53%( 5.3% (n=1) Unknown 20.0% (n=1) SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 38
39 SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 39
40 Statins Reduce: Stroke Atrial Fibrillationill Inflammatory Response from CPB SVG Disease Native CAD SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 40
41 EACTS 2010 Three-year Outcomes of the SYNTAX Trial Kappetein Slide 41
42 Conclusions How to Reduce Stroke With CABG Preoperative Screening Recognition of High Risk Patients Epiaortic Scanning on ALL Patients At Least Selective Use of Off Pump CABG No Touch Aortic Technique as Much As Possible Aggressive Treatment of AF Anticoagulation of Postoperative AF??? Aggressive Use of Statins Consider dual anti-platelet therapy (DAPT) especially with Off Pump SYNTAX: Stroke TCT 2009 M.J. Mack San Francisco, CA 22sep2009 Slide 42 42
Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX
Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX Maquet, Inc.,- unpaid consultant Cordis, Inc.,- unpaid consultant Boston Scientific, Inc.,- travel expenses paid for Syntax
More informationMichael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX
Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX Boston Scientific, Inc.- Syntax Trial Steering Committee Member- travel expenses paid by trial sponsor Maquet, Inc.- unpaid
More informationThe Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study Five-Year Results in the French Subset René Koning, MD On behalf of the SYNTAX investigators Three-year
More informationPTCA 1979: : I
The SYNTAX Message is Clear: CABG is Preferred in Complex MVD Angioplasty Summit TCTAP 2012 Seoul, Korea April 2012 David R. Holmes, MD Mayo Clinic Rochester, MN Presenter Disclosure Information David
More informationR&M Solutions
PCI with DES versus CABG & syntax score Dr. Mohamed Sobhy, MD, FACC, FESC Professor of Cardiology, Alexandria University, Egypt Head of Cardiology Department President of Egyptian Society of Cardiology
More informationImplications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011
Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011 Prof. Dr. Volkmar Falk Klinik für Herz- und Gefäßchirurgie, Universitätsspital Zürich, Schweiz In 2004 headlines were
More informationThe SYNTAX-LE MANS Study
The SYNTAX-LE MANS Study Synergy Between PCI with TAXUS Express and Cardiac Surgery: Late (15-month) Left Main Angiographic Substudy A. Pieter Kappetein, MD, PhD Erasmus MC, Rotterdam, NL SYNTAX-LE MANS
More informationQuality ID #166 (NQF 0131): Coronary Artery Bypass Graft (CABG): Stroke- National Quality Strategy Domain: Effective Clinical Care
Quality ID #166 (NQF 0131): Coronary Artery Bypass Graft (CABG): Stroke- National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome
More informationCORONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW
CONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW 2015 PQRS OPTIONS F MEASURES GROUPS: 2015 PQRS MEASURES IN CONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP: #43 Coronary Artery Bypass Graft (CABG):
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationEvidence-Based Management of CAD: Last Decade Trials and Updated Guidelines
Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland Conflict of Interests No conflict
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationCOMMENT DEFINIR UN PLURITRONCULAIRE. Didier Carrié CHU Toulouse Rangueil
COMMENT DEFINIR UN PLURITRONCULAIRE VISION ANGIOGRAHIQUE DU PLURITRONCULAIRE Didier Carrié CHU Toulouse Rangueil Congrès GRCI 03 Décembre 2010 Pôle Cardiovasculaire et Métabolique Avec quel œil je regarde
More informationApplication of Appropriate Use Criteria in Clinical Care of CAD. Peter K. Smith, MD Professor and Chief Thoracic Surgery Duke University 4/29/2012
Application of Appropriate Use Criteria in Clinical Care of CAD Peter K. Smith, MD Professor and Chief Thoracic Surgery Duke University 4/29/2012 Influence of Severity and Location of Stenosis on Cardiac
More informationDownloaded from:
Annemans, L; Danchin, N; Van de Werf, F; Pocock, S; Licour, M; Medina, J; Bueno, H (2016) Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationMise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD
Mise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD Columbia University Medical Center and The Cardiovascular Research Foundation, New York, USA Hôpital du Sacré-Coeur de Montréal,
More informationhigh SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin Turin / Italy
What to do with patients with high SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin San Giovanni Battista Hospital Turin / Italy Who are the patients with high SYNTAX
More informationQuality Measures MIPS CV Specific
Quality Measures MIPS CV Specific MEASURE NAME Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy CAHPS for MIPS Clinician/Group Survey Cardiac Rehabilitation Patient Referral from
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationIschemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 89) is a regional and national referral center for percutaneous coronary intervention (PCI). A total of
More informationSurgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome
Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures
More informationEACTS Adult Cardiac Database
EACTS Adult Cardiac Database Quality Improvement Programme List of changes to Version 2.0, 13 th Dec 2018, compared to version 1.0, 1 st May 2014. INTRODUCTORY NOTES This document s purpose is to list
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial
compared with clopidogrel in patients with acute coronary syndromes the PLATelet Inhibition and patient Outcomes trial Outcomes in patients with and planned PCI Ph.Gabriel Steg*, Stefan James, Robert A
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationOn-Pump vs. Off-Pump CABG: The Controversy Continues. Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery
On-Pump vs. Off-Pump CABG: The Controversy Continues Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery On-pump vs. Off-Pump CABG: The Controversy Continues Conflict
More informationTHE NATIONAL QUALITY FORUM
THE NATIONAL QUALITY FORUM National Voluntary Consensus Standards for Patient Outcomes Table of Measures Submitted-Phase 1 As of March 5, 2010 Note: This information is for personal and noncommercial use
More informationBetter CABGs vs Better PCI Devices
CABG vs PCI 2017 Multivessel Coronary Disease Better CABGs vs Better PCI Devices ACC New York, Dec 8, 2017 No Disclosures CABG vs PCI 2017 Stable Multivessel Coronary Disease 1. Are These The two Critical
More informationIschemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 11,61) is a regional and national referral center for percutaneous coronary intervention (PCI). A total
More informationQuality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
More informationLeft Main Intervention: Where are we in 2015?
Left Main Intervention: Where are we in 2015? David A. Cox, MD FSCAI Director, Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown, PA Fall Fellows Course Laa
More informationMost Patients with Elective Left Main Disease. Farrel Hellig
Most Patients with Elective Left Main Disease Should be Treated with PCI! Farrel Hellig Sunnnghill and Sunward Park Hospitals Johannesburg South Africa Everything that can be invented has been invented
More informationCase Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?
Cronicon OPEN ACCESS CARDIOLOGY Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Valentin Hristov* Department of Cardiology, Specialized
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationAdvances in Cardiovascular Diagnosis and Therapy. No disclosure or conflicts. Outline
Advances in Cardiovascular Diagnosis and Therapy Firas Zahr, MD Assistant Professor of Medicine Interventional Cardiology University Of Iowa No disclosure or conflicts Outline What is new with revascularization?
More informationNon-Selective Carotid Artery Ultrasound Screening in Patients Undergoing Coronary Artery Bypass Grafting: Is It Necessary?
Non-Selective Carotid Artery Ultrasound Screening in Patients Undergoing Coronary Artery Bypass Grafting: Is It Necessary? Khalil Masabni, Joseph F. Sabik III, Sajjad Raza, Theresa Carnes, Hemantha Koduri,
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationAbbott Vascular. PROTOCOL EXCEL Clinical Trial
Abbott Vascular PROTOCOL Clinical Trial Evaluation of XIENCE PRIME or XIENCE V versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization PCI (1 st gen DES) vs. CABG for Left
More informationLeft Main Intervention: Will it become standard of care?
Left Main Intervention: Will it become standard of care? David Cox, MD FSCAI, FACC Director, Interventional Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown,
More informationUnprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy
Unprotected Left Main Stenting: Patient Selection and Recent Experience Alaide Chieffo S. Raffaele Hospital, Milan, Italy Class IIa (Level B) AHA/ACC 2005 Guidelines Left Main CAD The use of PCI for pts
More informationDeclaration of conflict of interest NONE
Declaration of conflict of interest NONE Claudio Muneretto MD, PhD Director of Division of Cardiac Surgery University of Brescia Medical School Italy Hybrid Chymera Different features and potential advantages
More informationHOW TO PREPARE A GOOD ACCEPTED
HOW TO PREPARE A GOOD ABSTRACT AND GET IT ACCEPTED This is an interactive session; be free to interrupt and ask questions at any time during the talk! Some useful points when deciding if and where to submit
More information6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS
PREVENTING HOSPITAL READMISSIONS IN CARDIOVASCULAR PATIENTS Christina Cortez Perry, MSN, FNP-C, CCCC Cardiology Coordinator- Corpus Christi Medical Center 1 2 LEARNING OBJECTIVES Identify the target patient
More informationCan Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More information'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'
'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome' Miguel Sousa Uva Chair ESC Cardiovascular Surgery WG Hospital da Cruz Vermelha Portuguesa
More informationProgram Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
More informationStrokes After TAVR Reasons for Declining Frequency
Strokes After TAVR Reasons for Declining Frequency Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory Cleveland Clinic Disclosure NONE Second Generation Valves Newer
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationTRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital
TRIAL UPDATE 1 ISAR TRIPLE SECURITY Trial Dr Deven Patel Royal Free Hospital NO CONFLICT OF INTEREST TO DECLARE ISAR TRIPLE Comparison of 6 weeks vs 6 months Triple Therapy in patients on oral anticoagulation
More informationThe ESC Registry on Chronic Ischemic Coronary Disease
EURObservational Research Programme The ESC Registry on Chronic Ischemic Coronary Disease Prof. Fausto J. Pinto, FESC, FACC, FASE, FSCAI Immediate Past-President, ESC University Hospital Sta Maria University
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationClinical Controversies in Perioperative Medicine
Clinical Controversies in Perioperative Medicine Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Predicting & Managing Cardiac Risk A 70-y.o. man with progressive
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More informationGRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017
GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional
More informationManaging Hypertension in the Perioperative Arena
Managing Hypertension in the Perioperative Arena Optimizing Perioperative Management Strategies for Hypertension in the Cardiac Surgical Patient Objectives: Treatment of hypertensive emergencies. ALBERT
More informationImproved CABG for Complex CAD: A Perspective of Coming Back
Improved CABG for Complex CAD: A Perspective of Coming Back John D. Puskas, MD, MSc, FACS, FACC Professor of Cardiothoracic Surgery, Icahn School of Medicine at Mount Sinai Chairman, Department of Cardiac
More informationIncidence of Postoperative Atrial Fibrillation after minimally invasive mitral valve surgery
Incidence of Postoperative Atrial Fibrillation after minimally invasive mitral valve surgery JUAN S. JARAMILLO, MD Cardiovascular Surgery Clinica CardioVID Medellin Colombia DISCLOSURE INFORMATION Consultant
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #44 (NQF 0236): Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More information2/17/2010. Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco
Modern Management of Patients with Stable Coronary Artery Disease Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco Scope of the Problem Prevalence of CAD: 17.6 million
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationRandomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David
More informationManagement of High-Risk CAD : Surgeons Perspective
Management of High-Risk CAD : Surgeons Perspective Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan Conflict : Cardiac Surgeon! High Risk CABG 77 year old with prior large anterior
More informationTEVAR, TAVR, OPCAB; IS THE PUMP (AND THE PERFUSIONIST) BECOMING OBSOLETE? Michael Mack, M.D. Baylor Healthcare System Dallas, TX April 28, 2012
TEVAR, TAVR, OPCAB; IS THE PUMP (AND THE PERFUSIONIST) BECOMING OBSOLETE? Michael Mack, M.D. Baylor Healthcare System Dallas, TX April 28, 2012 Conflict of Interest Disclosure Uncompensated Member of the
More informationWhen should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER
When should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER ICPS, Massy ICV-GVM La Roseraie, Aubervilliers Hôpital FOCH, Suresnes Disclosure Statement of Financial
More informationCoronary Artery Bypass Grafting in Diabetics: All Arterial or Hybrid?
Coronary Artery Bypass Grafting in Diabetics: All Arterial or Hybrid? Dr. Daniel Navia M.D. Chief Cardiac Surgery Department ICBA, Buenos Aires Argentina, 2018 No disclosures 2 Current evidence The FREEDOM
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationPractice-Level Executive Summary Report
PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular
More informationCHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand
CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationQuinn Capers, IV, MD
Heart Attacks Mended Hearts Presentation, January, 2017 Quinn Capers, IV, MD Associate Professor of Medicine (Cardiovascular Medicine) Director, Transradial Coronary Interventions Division of Cardiovascular
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationDR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI
The Impact of AF on Natural History of CAD DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI CAD MOST COMMON CARDIOVASCULAR DISEASE MOST COMMON CAUSE OF DEATH
More informationNorth Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease
Guidelines on oral antiplatelet therapy in cardiovascular disease This guidance should be considered as one part of the wider therapeutic management of patients. The indication for antiplatelet therapy
More informationTRIAS HR Pilot Study
Late Breaking Clinical Trials TCT, October 22 nd 27, Washington, USA TRIAS HR Pilot Study RCT comparing Genous EPC capturing stent with Taxus Paclitaxel eluting stent Robbert J de Winter MD PhD FESC Academic
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationDrug eluting stents From revolution to evolution. Current limitations
Drug eluting stents From revolution to evolution Current limitations Eric Eeckhout Centre Hospitalier Universitaire Vaudois Lausanne - Switzerland eric.eeckhout@chuv.ch Overview Historical perspective
More informationQuality Payment Program: Cardiology Specialty Measure Set
Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor
More informationThe Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina
The Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina Ajay J. Kirtane,, MD Columbia University Medical Center The Cardiovascular Research Foundation Conflict of Interest
More informationIntraoperative application of Cytosorb in cardiac surgery
Intraoperative application of Cytosorb in cardiac surgery Dr. Carolyn Weber Heart Center of the University of Cologne Dept. of Cardiothoracic Surgery Cologne, Germany SIRS & Cardiopulmonary Bypass (CPB)
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationPercutaneous Coronary Interventions Without On-site Cardiac Surgery
Percutaneous Coronary Interventions Without On-site Cardiac Surgery Hassan Al Zammar, MD,FESC Consultant & Interventional Cardiologist Head of Cardiology Department European Gaza Hospital Palestine European
More informationImpact of statins and beta-blocker therapy on mortality after coronary artery bypass graft surgery
Original Article Impact of statins and beta-blocker therapy on mortality after coronary artery bypass graft surgery Femi Philip 1, Eugene Blackstone 2, Samir R. Kapadia 2 1 Department of Cardiovascular
More informationClinical Controversies in Perioperative Medicine
Clinical Controversies in Perioperative Medicine Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Cardiac Evaluation: New Guidelines A 70-y.o. man with progressive
More informationChairman and O. Wayne Isom Professor Department of Cardiothoracic Surgery Weill Cornell Medicine
Leonard N. Girardi, M.D. Chairman and O. Wayne Isom Professor Department of Cardiothoracic Surgery Weill Cornell Medicine New York, New York Houston Aortic Symposium Houston, Texas February 23, 2017 weill.cornell.edu
More informationSpecial Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원
Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Issues on Patients with NOAC PCI Peri-procedural management CKD or dialysis Cardioversion Neurological situations Dual Antiplatelet Therapy with Oral Anticoagulants
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More information